Urology
Volume 72, Issue 1 , Pages 3-9 , July 2008

Does “Normal” Aging Imply Urinary, Bowel, and Erectile Dysfunction? A General Population Survey

  • Ida J. Korfage

      Affiliations

    • Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
    • Corresponding Author InformationReprint requests: Ida J. Korfage, Ph.D., Department of Public Health, Erasmus MC, University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, the Netherlands.
    • ,
  • Monique Roobol

      Affiliations

    • Department of Urology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
    • ,
  • Harry J. de Koning

      Affiliations

    • Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
    • ,
  • Wim J. Kirkels

      Affiliations

    • Department of Urology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
    • ,
  • Fritz H. Schröder

      Affiliations

    • Department of Urology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
    • ,
  • Marie-Louise Essink-Bot

      Affiliations

    • Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands

Received 22 June 2007 ,Accepted 23 January 2008.

References 

  1. Litwin MS, Hays RD, Fink A, et al. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care. 1998;36:1002–1012
  2. Wei JT, Dunn RL, Litwin MS, et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56:899–905
  3. Esper P, Mo F, Chodak G, et al. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1997;50:920–928
  4. Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 2004;96:1358–1367
  5. Penson D, Feng Z, Kuniyuki A, et al. General quality of life 2 years following treatment for prostate cancer: what influences outcomes? (Results from the prostate cancer outcomes study). J Clin Oncol. 2003;21:1147–1154
  6. Schapira MM, Lawrence WF, Katz DA, et al. Effect of treatment on quality of life among men with clinically localized prostate cancer. Med Care. 2001;39:243–253
  7. Korfage IJ, Essink-Bot ML, Borsboom GJ, et al. Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer. 2005;116:291–296
  8. Donovan J, Mills N, Smith M, et al. Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study (Commentary: presenting unbiased information to patients can be difficult). BMJ. 2002;325:766–770
  9. Roobol MJ, Kirkels WJ, Schroder FH. Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). BJU Int. 2003;2(92 Suppl):48–54
  10. Wei JT, Dunn RL, Litwin MS, et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56:899–905
  11. Korfage IJ, Essink-Bot ML, Madalinska JB, et al. Measuring disease specific quality of life in localized prostate cancer: the Dutch experience. Qual Life Res. 2003;12:459–964
  12. Slob AK, Blom JH, van der Werff ten Bosch JJ. Erection problems in medical practice: differential diagnosis with relatively simple method. J Urol. 1990;143:46–50
  13. Ware JEJ, Snow KK, Kosinski M, et al. SF-36 health survey: manual and interpretation guide. Boston, MA: The Health Institute, New England Medical Center; 1993;
  14. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582–592
  15. Dunn RL, Wei JT, Morgan D. In: Minimally Importand Difference for the Incontinence Severity Index (ISI): International Society of Quality of Life Research. vol. 15:2006;p. A-75;Lissabon, Portugal
  16. Rerkpattanapipat P, Stanek MS, Kotler MN. Sex and the heart: what is the role of the cardiologist?. Eur Heart J. 2001;22:201–208
  17. Grover SA, Lowensteyn I, Kaouache M, et al. The prevalence of erectile dysfunction in the primary care setting: importance of risk factors for diabetes and vascular disease. Arch Intern Med. 2006;166:213–219
  18. Ponholzer A, Temml C, Mock K, et al. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur Urol. 2005;47:80–85discussion 85–86
  19. Litwin MS. Health related quality of life in older men without prostate cancer. J Urol. 1999;161:1180–1184
  20. Prins J, Blanker MH, Bohnen AM, et al. Prevalence of erectile dysfunction: a systematic review of population-based studies. Int J Impot Res. 2002;14:422–432
  21. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822–830
  22. Rosen RC, Fisher WA, et al. ; and Men's Attitudes to Life Events and Sexuality Study: The multinational Men's Attitudes to Life Events and Sexuality (MALES) study I: prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin. 2004;20:607–617
  23. Hoffman RM, Stone SN, Espey D, et al. Differences between men with screening-detected versus clinically diagnosed prostate cancers in the USA. BMC Cancer. 2005;5:27–35
  24. Otto SJ, Schroder FH, de Koning HJ. Risk of cardiovascular mortality in prostate cancer patients in the rotterdam randomized screening trial. J Clin Oncol. 2006;24:4184–4189
  25. Cronin KA, Weed DL, Connor RJ, et al. Case-control studies of cancer screening: theory and practice. J Natl Cancer Inst. 1998;90:498–504

 Funding for the study was provided by the Dutch Cancer Society (EUR 2000-2329) and the Netherlands Organization for Health Research and Development ‘ZonMw' (2000-2-1016).

PII: S0090-4295(08)00139-8

doi: 10.1016/j.urology.2008.01.058

Urology
Volume 72, Issue 1 , Pages 3-9 , July 2008

Article Tools

* Image Usage & Resolution